Side effects due to primary antituberculosis drugs during the initial phase of therapy in 1149 hospitalized patients for tuberculosis

Respiratory Medicine

Volumn 100, Issue 10, 2006, Pages 1834-1842

  Gülbay, Banu Eriş ^a   Gürkan, Özlem Ural ^a   Yildiz, Öznur Akkoca ^a   Önen, Zeynep Pinar ^a   Erkekol, Ferda Öner ^a   Baççioǧlu, Ayşe ^a   Acican, Turan ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Antituberculosis (anti TB) drugs; Hepatotoxicity; Hyperuricemia; Neuropsychiatric manifestations; Ototoxicity; Side effects

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; ETHAMBUTOL; ISONIAZID; LOOP DIURETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ABDOMINAL PAIN; ABSCESS; ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTHRALGIA; ARTICLE; ATAXIA; BALANCE DISORDER; BILIRUBIN BLOOD LEVEL; BLOOD CELL COUNT; CONCENTRATION LOSS; CONTROLLED STUDY; DIET THERAPY; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG WITHDRAWAL; DYSPHORIA; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HEARING LOSS; HEMOLYSIS; HEPATITIS; HOSPITAL PATIENT; HUMAN; HYDRATION; HYPERURICEMIA; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; LIVER DYSFUNCTION; LIVER TOXICITY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MEASLES LIKE RASH; MEDICAL RECORD; MEMORY DISORDER; NAUSEA; OBSESSIVE COMPULSIVE DISORDER; OTOTOXICITY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PRURITUS; PSYCHOPATHY; PSYCHOSIS; RETROBULBAR OPTIC NEUROPATHY; RETROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE; SKIN MANIFESTATION; TINNITUS; VERTIGO; VISUAL IMPAIRMENT; VOMITING;

ADOLESCENT; ADULT; AGED; ANTITUBERCULAR AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; HYPERURICEMIA; INFANT; INFANT, NEWBORN; LIVER DISEASES; MALE; MENTAL DISORDERS; MIDDLE AGED; OTORHINOLARYNGOLOGIC DISEASES; RETROSPECTIVE STUDIES; TUBERCULOSIS, PULMONARY;

EID: 33747867798     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2006.01.014     Document Type: Article

References (29)

1. Centers for Disease Control and Prevention. American Thoracic Society, CDC, and Infectious Diseases Society of America. Treatment of tuberculosis. Morbidity Mortality Weekly Rep (MMWR) 52 RR-11 (2003) 1-77
2. Myers J.P. New recommendations for the treatment of tuberculosis. Curr Opin Infect Dis 18 (2005) 133-140
3. Schaberg T., Rebhan K., and Lode H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J 9 (1996) 2026-2030
4. Dossing M., Wilcke J.T., Askgaard D.S., and Nybo B. Liver injury during antituberculosis treatment: an 11-year study. Tuberc Lung Dis 77 (1996) 335-340
5. Tahaoglu K., Atac G., Sevim T., Tarun T., Yazicioglu O., Horzum G., et al. The management of anti-tuberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis 5 (2001) 65-69
6. Inoue T., Ikeda N., Kurasawa T., et al. Hyperuricemia and arthralgia during pyrazinamide treatment (Abstract). Nihon Kokyuki Gakkai Zasshi 37 (1999) 115-118 [article in Japanese]
7. Yee D., Valiquette C., Pelletier M., et al. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 167 (2003) 1472-1477
8. Ormerod L.P., and Horsfield N. Frequency and type of reactions to antituberculosis drugs: observations in routine treatment. Tuber Lung Dis 77 (1996) 37-42
9. Steele M.A., and Des Prez R.M. The role of pyrazinamide in tuberculosis chemotherapy. Chest 94 (1988) 845-850
10. Papastavros T., Dolovich L.R., Holbrook A., Whitehead L., and Loeb M. Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis. CMAJ 167 (2002) 131-136
11. De Jager P., and Van Altena R. Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis. Int J Tuberc Lung Dis 6 (2002) 622-627
12. Sharma S.K., Balamurugan A., Saha P.K., Pandey R.M., and Mehra N.K. Evaluation of clinical and immunogenetic risk factorsfor the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 166 (2002) 916-919
13. Ungo J.R., Jones D., Ashki{dotless}n D., Hollender E.S., Bernstein D., Albanese A.P., et al. Antituberculosis drug-induced hepatotoxicity the role of hepatitis C virus and the human immunodeficiency virus. Am J Respi{dotless}r Cri{dotless}t Care Med 157 (1998) 1871-1876
14. Turktas H., Unsal M., Tulek N., and Oruc O. Hepatotoxicity of antituberculosis therapy (rifampicin, isoniazid and pyrazinamide) or viral hepatitis. Tuber Lung Dis 75 (1994) 58-60
15. Devoto F.M., Gonzalez C., Iannantuono R., Sera H.A., Gonzalez C.D., and Saenz C. Risk factors for hepatotoxicity induced by antituberculosis drugs. Acta Physiol Pharmacol Ther Latinoam 47 (1997) 197-202
16. Teleman M.D., Chee C.B., Earnest A., and Wang Y.T. Hepatotoxicity of tuberculosis chemotherapy under general programme conditions in Singapore. Int J Tuberc Lung Dis 6 (2002) 699-705
17. Stout J.E., Engemann J.J., Cheng A.C., Fortenberry E.R., and Hamilton C.D. Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis. Am J Respir Crit Care Med 167 (2003) 824-827
18. Thompson N.P., Caplin M.E., Hamilton M.I., Gillespie S.H., Clarke S.W., Burroughs A.K., et al. Anti-tuberculosis medication and the liver: dangers and recommendations in management. Eur Respir J 8 (1995) 1384-1388
19. Pande J.N., Singh S.P., Khilnani G.C., and Khilnani Si Tandon R.K. Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax 51 (1996) 132-1366
20. Wong W.M., Wu P.C., Yuen M.F., Cheng C.C., Yew W.W., Wong P.C., et al. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology 31 (2000) 201-206
21. Lee W.M. Drug-induced hepatotoxicity. N Engl J Med 349 (2003) 474-485
22. Ohkawa K., Hashiguchi M., Ohno K., Kiuchi C., Takahashi S., Kondo S., et al. Risk factors for antituberculous chemotherapy-induced hepatotoxicity in Japanese pediatric patients. Clin Pharmacol Ther 72 (2002) 220-226
23. Lobue P.A., and Moser K.S. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med 168 (2003) 443-447
24. Nolan C.M., Goldberg S.V., and Buskin S.E. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 17 (1999) 1014-1018
25. Aktogu S., Yorganci{dotless}oglu A., Çi{dotless}rak K., Kose T., and Dereli S.M. Clinical spectrum of pulmonary and pleural tuberculosis: a report of 5480 cases. Eur Respir J 9 (1996) 2031-2035
26. Mcneill L., Allen M., Estrada C., and Cook P. Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis improved completion rates but more hepatotoxicity. Chest 123 (2003) 102-106
27. Furin J.J., Mitnick C.D., Shin S.S., et al. Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis. Int J Tuberc L ung Dis 5 (2001) 648-655
28. Quantrill S.J., Woodhead M.A., Hardy C.C., Hardy C.C., Hutchison A.J., and Gokal R. Side-effects of antituberculosis drug treatment in patients with chronic renal failure. Eur Respir J 20 (2002) 440-443
29. Jasmer R.M., Saukkonen J.J., Blumberg H.M., Daley C.L., Bernardo J., Vittinghoff E., et al. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med 137 (2002) 640-647